SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma plans to raise Rs 12,000 crore via QIP

07 Oct 2015 Evaluate

Sun Pharmaceutical Industries is planning to raise up to Rs 12,000 crore through convertible debentures or a qualified institutional placement (QIP). In this regard, the company is seeking shareholder approval.

The company will use the raised fund for expansion and acquisitions. The company would allow it to strengthen its financial resources and net worth. Following the merger with Ranbaxy Pharmaceuticals, the company has been restructuring its business and rationalizing its manufacturing footprint.

Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. The company provides high quality, affordable medicines trusted by healthcare professionals and patients in over 150 countries worldwide.

Sun Pharma Inds. Share Price

1648.00 -31.85 (-1.90%)
24-Apr-2026 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1648.00
Dr. Reddys Lab 1323.20
Cipla 1289.70
Zydus Lifesciences 937.70
Lupin 2330.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×